[Polymer and oligomer based doxorubicin carriers]

Area of Science:

• Oncology
• Polymer Chemistry
• Pharmacology

Background:

• Doxorubicin is a vital chemotherapy drug but causes cardiotoxicity.
• Cardiotoxicity limits doxorubicin's clinical use, occurring at cumulative doses of 450-600 mg/m2.
• Developing safer drug delivery systems is crucial for cancer treatment.

Purpose of the Study:

• To review advanced polymer and oligomer carrier strategies for doxorubicin delivery.
• To explore methods for improving anticancer selectivity and reducing drug toxicity.
• To present promising formulations for enhanced anthracycline drug delivery.

Main Methods:

• Review of polymer-drug conjugate strategies.
• Analysis of drug delivery systems including liposomes, prodrugs, and polymer conjugates.
• Examination of polyethylenoglycol-coated liposomal doxorubicin.
• Investigation of peptide-drug conjugates and glycosaminoglycan-coated doxorubicin.
• Study of doxorubicin conjugates with N-(2-hydroxypropyl)methacrylamide copolymers.

Main Results:

• Polymer carriers offer improved pharmacokinetic profiles compared to small molecule drugs.
• Drug delivery systems like pegylated liposomal doxorubicin show better therapeutic effects.
• Multifunctional polymers can mask and release cytotoxic agents at target sites.
• Specific formulations reviewed include pegylated liposomal doxorubicin, peptide-drug conjugates, glycosaminoglycan-coated doxorubicin, and N-(2-hydroxypropyl)methacrylamide copolymer conjugates.

Conclusions:

• Polymer and oligomer carriers represent a promising strategy to improve doxorubicin's therapeutic index.
• These advanced formulations aim to enhance efficacy while mitigating cardiotoxicity.
• Further development of polymer-based drug delivery systems holds significant potential for cancer therapy.